** Drug developer Sage Therapeutics' shares fall 4.3% to $4.70 premarket ** Company says it will stop further development of its experimental drug, dalzanemdor, after it did not meet main goal in a mid-stage trial
** Sage was testing the drug to treat cognitive impairment associated with Huntington's disease, which causes nerve cells in the brain to decay over time
** 2 of 20 brokerages rate the stock "buy", 16 "hold" and 2 "sell"; median PT $9 - LSEG
** As of last close, stock down 77.3% YTD
(Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。